Michael J. Birrer, MD, PhD, Director of the University of Alabama at Birmingham Comprehensive Cancer Center gives an overview of presentation that involves the use of avelumab in patients with endometrial cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract TPS5615: Phase 2, two-group, two-stage, open-label study of avelumab in patients with microsatellite stable, microsatellite instable and POLE-mutated recurrent or persistent endometrial cancer
Advertisement